EBD Group is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
Key Sessions

Darren Ji

The transformational change within China's biopharma industry

Roche

Joseph Damond

Value and the pricing of innovation

Biotechnology Innovation Organization (BIO)

07:45 18:30 (645 mins)

Main agenda

Registration and Exhibition open

Registration: Level 0, Boulevard

Exhibtion: Level 0, Hall 7

07:45 10:30 (165 mins)

Main agenda

Continental Breakfast

Level 0, Hall 7

09:00 10:30 (90 mins)

Main agenda

The transformational change within China's biopharma industry

Location: Level 2, Room 3

China, never short of changes, is going through a major transformation in the pharmaceutical industry. In the past twelve months, the central government has redefined regulatory classifications of drug categories; for the first time a pilot initiative was started to allow separation of the market authorization holder from the drug manufacturing holder; the government also mandated the drug sales process into a "two invoice system," which fundamentally cut off the layers of resales in the middle of the market supply chain. This is in the context of tremendous infusion of capital into the biotech sector, by both government-backed life science funds and private money which seeks new avenues to duplicate their investment returns from other sectors. Meanwhile the return of scientists trained overseas continues to supply the entrepreneurial pool for new startups.  

The changes are undoubtedly dazzling in this lucrative pharmaceutical market. What does it mean to the companies that are strategically poised to develop in China? In this panel a group of renowned industry leaders discusses the good, the bad and the ugly of the ever-evolving China. By diving deep into the changes through real life experiences we hope to peel open the challenges and opportunities in developing a viable and sustainable business in this big and growing market.


  • Moderator Darren Ji - Global Head and VP, Roche Partnering Asia and Emerging Markets, Roche
  • Panelist Rüdiger Herrmann - Partner, Dechert LLP
  • Panelist Yuwen Liu - Founding Partner, Bohe Angel Fund
  • Panelist Robert Narquizian - Managing Director, ChinaBio® Group
  • Panelist Philip Xiao - Founder and CEO, Profex
  • Panelist Dan Zhang - Founder, Chairman and CEO, Fountain Medical, China

09:00 10:30 (90 mins)

Main agenda

Access strategies for shifting markets

Location: Level 2, Room 4

Much has been said about the widening range of patient, payer and policy makers acting within the biotech sphere and how the inclusion of new voices broadens market access opportunities for industry. It also means the processes and pathways to market are shifting to incorporate these emerging players.  How have these emerging models of collaboration altered the discussion around market access and what does it mean for the practicalities of getting a product to patients? How will policy emerging from a new US government affect market access for biotech companies? How can biotech better communicate its goals, partner with relevant organizations and balance risk for sustainable success?


  • Moderator Joseph Damond - Senior VP, International Affairs, Biotechnology Innovation Organization (BIO)
  • Panelist Barbara Freischem - Executive Director, EBE
  • Panelist Alexander Natz - Secretary General, EUCOPE
  • Panelist Nigel Thompson - Senior Advisor, Albright Stonebridge Group

09:00 10:30 (90 mins)

Main agenda

Big Pharma's approach to digital medicine

Location: Level 2, Room 1

The convergence of new technologies and therapies is reshaping the entire landscape of healthcare. Panelists will share their perspectives on how therapeutic applications, clinical trials, drug delivery, and adherence will be altered by digital medicine's influence.


  • Moderator Nima Jokilaakso - Project Manager, Swecare
  • Panelist Alexandra Eberhard - Managing Director Europe, Executive VP Sciences, Signal Analytics
  • Panelist Tracy Mayne - Head of Medical Affairs Strategic Research, Purdue Pharma L.P.
  • Panelist Peter Neubeck - Chief Medical Officer, ExB Labs
  • Panelist Matthew Owens - Global Head Legal, Strategic Partnerships and Digital Medicine, Novartis

09:00 10:30 (90 mins)

Main agenda

Covering all the bases: An integrated approach to strategic drug development

Location: Level 2, Room 2

The science behind biotech therapies is only the starting point of drug development. Four other elements are essential for a drug to end up in the hands of the patient: a commercialization strategy, a financial road map, a regulatory plan and a business development strategy. Each of these elements, from manufacturing to funding, reimbursement to partnership management, requires expertise and careful integration. This workshop will work through how these four dimensions of drug development not only contribute to success but also how they need to work together in order for scientific and commercial success.


  • Moderator Ann Baker - VP, Life Sciences Practice, Charles River Associates
  • Panelist Johannes Clemens - Key Account Manager, Vetter
  • Panelist Christelle Dagoneau - Director, Business Development, Catalent
  • Panelist Berthold Hinzen - Head Business Development and Licensing, General Medicine, Bayer Pharma
  • Panelist Peter Sausen - VP, Early Phase Development Solutions, Covance

10:00 10:30 (30 mins)

Main agenda

NRW – Biotech Hotspot after 20 years of BioRegions - Press Conference

Level 0, Hall 7, Booth 100

  • Speaker Dr. Sandra Klausing - Director Scientific innovations & USP, Xell AG
  • Speaker Jörg Möller - Member, Executive Committee Pharmaceuticals Division and Head of Development, Bayer AG
  • Speaker Svenja Schulze - Minister, Ministry of Innovation, Science and Research of the State of North Rhine-Westphalia

10:00 18:30 (510 mins)

Main agenda

One-to-one Meetings

10:45 11:15 (30 mins)

Main agenda

Welcome and Opening Remarks

Location: Level 0, Konrad Adenauer Saal

  • Speaker Anna Chrisman - Group Managing Director, EBD Group
  • Speaker Dr. Bernward Garthoff - Representative for Biotechnology of the State of North Rhine-Westphalia, Cluster BIO.NRW
  • Speaker Svenja Schulze - Minister, Ministry of Innovation, Science and Research of the State of North Rhine-Westphalia
  • Speaker David Thomas - Director, Industry Research and Analysis, Biotechnology Innovation Organization (BIO)

11:15 12:30 (75 mins)

Main agenda

Value and the pricing of innovation

Location: Level 0, Konrad Adenauer Saal

Balancing the cost of innovation and ensuring access to high-quality, effective medical treatment continues to be a challenge for all modern healthcare systems. Significant shifts in global and local market dynamics, policy and politics are prompting a discussion about other dimensions of value, be they economic, social, or scientific. Different markets are at different stages of this discussion. While some countries in Europe already have mechanisms in place to assess drugs within an established framework of measures, others are grappling with workable systems of assessment and their repercussions. Can these forerunners inform the discussion in other geographies? How can biotech innovators best demonstrate the value of their therapies so that outcomes are measurable and relevant to all stakeholders? These and other questions will be discussed by our panel of experts.

  • Moderator Joseph Damond - Senior VP, International Affairs, Biotechnology Innovation Organization (BIO)
  • Panelist Kate Bingham - Managing Partner, SV Life Sciences Advisers
  • Panelist Jörg Möller - Member, Executive Committee Pharmaceuticals Division and Head of Development, Bayer AG
  • Panelist Juergen Windeler - Director, Institute for Quality and Efficiency in Health Care, IQWiG

12:00 14:00 (120 mins)

Main agenda

Luncheon

Level 0, Hall 7 (Exhibition area, Rear area) and Level 0, Restaurant, Boulevard

13:30 18:00 (270 mins)

Main agenda

Hear the latest partnering opportunities from global pharma companies

Level 0 – Konrad Adenauer Saal

13:30 – Boehringer Ingelheim  Paola Casarosa , Corporate Vice President Business Development & Licensing

13:45 – Novartis – Markus Kalousek, S&E Head Immunology, Dermatology & Transplantation, BD&L

14:00 – Johnson & Johnson – Kurt Hertogs, J&J Innovation Lead Beerse Campus

14:15 – Bayer   Dimitrij Hristodorov, Director, Early Licensing

14:30 – Eli Lilly and Company – Johnston Erwin, Vice President, Corporate Business Development 

14:45 – Roche – Lesley Bester, Business Development Director, Infectious Disease, Immunology and Speciality Care, Roche Partnering, F.Hoffmann-La Roche Ltd.

15:00 – Genentech – Angele Maki, Associate Director Genentech Partnering

15:15 – Sanofi – Sarah Holland, Head of Europe, External Science and Partnering

15:30 – Merck – Chris Hamann, Head of BD General Medicine and Regional

15:45 – Pfizer – Nathalie ter Wengel, European Head Global Scouting External R&D Innovation

16:00 – AbbVie – Anna Maroney

16:15 – Bristol-Myers Squibb – Paul Biondi, SVP, Head of Business Development

16:30 – Takeda Pharmaceuticals Company Ltd. – Kleem Chaudary, Senior Director Business Development

16:45 – Amgen – Ray Barlow, Executive Director

17:00 – Shire – Tibor Papp, Hematology/Oncology Transactions Lead

17:15 – Novo Nordisk – Tomas Landh, Innovation Scourcing VP, Senior Prinicpal Scientist

17:30 – MSD – Reza Halse, Head European Innovation Hub

17:45 – Purdue Pharma – Kathryn Gregory, Executive Director, Licensing & Business Development, Purdue Pharma L.P. 

13:30 14:30 (60 mins)

Main agenda

Curing cancer with cell and gene therapies

Level 2, Room 4

Advances in cell and gene therapies are changing the way cancer is being treated and the goal of developing cures may soon be a reality. With new techniques that can edit specific genetic code or deploy armies of T cells, we are entering an era in medicine that has the potential to impact millions of lives. Leading companies will discuss the current landscape and what we can expect to see in the next five years as more products are entering human studies.

  • Moderator Douglas MacDougall - President, MacDougall Biomedical Communications
  • Panelist Julia Berretta - VP, Business Development, Cellectis
  • Panelist Joern-Peter Halle - SVP, Head of External Innovation, Biopharma Global R&D, Merck KGaA
  • Panelist Neill Moray Mackenzie - Chairman, Cellular Therapeutics Ltd
  • Panelist Wenyong Wang - VP, Business Development, Adaptimmune

14:45 15:45 (60 mins)

Main agenda

The pathway to commercialization for cell and gene therapies

Level 2, Room 4

  • Moderator Mike Ward - Global Director of Content, Informa Pharma Insights
  • Panelist Oliver Bartelsen - Global Head, Business Development and Industrial Services, Miltenyi Biotec GmbH
  • Panelist Doug Doerfler - President and CEO, MaxCyte
  • Panelist David Ewbank - VP, Strategy Consulting, INC Research
  • Panelist Jonathan Garen - Chief Business Officer, UniQure
  • Panelist Alexandra Richardson - Head, Business Development, Clayton Biotechnologies, Inc

16:00 17:00 (60 mins)

Main agenda

Patient engagement to unlock the promise of cell and gene therapies

Level 2, Room 4

Innovative science is one key to the development of novel therapies but innovative models of working with patients are also critical. From fundraising to clinical trials to advocacy, patients have taken a more active role than ever before. How are companies changing their strategies to leverage the “power of the patient”? How are patients empowering themselves and working with industry to bring new treatments to the market?

  • Moderator Timothy Cote - Principal and CEO, Coté Orphan
  • Panelist Julie Venners Christensen - Head of Global Patient Advocacy, Rare Diseases, GlaxoSmithKlein
  • Panelist Morrie Ruffin - Managing Director, Alliance for Regenerative Medicine
  • Panelist Bernadette Tosti - Head, Patient Recruitment Programs, Quintiles

17:15 18:15 (60 mins)

Main agenda

Immunotherapies: Partnership models driving cures

Level 2, Room 4

While we have seen new immunotherapies enter the market and there are many exciting products in development; we have also seen recent setbacks. The field is risky and partnerships among biotechs, pharmas, and other stakeholders are critical in bringing the next generation of treatments to fruition. How can companies work together to minimize the risk, maximize the potential, and ultimately help patients? Panelists will highlight new models of collaboration that can bring exciting new science to new treatments and cures.

  • Moderator Jeffrey Bockman - VP, Defined Health
  • Panelist Paul Biondi - Senior VP, Head of Business Development, Bristol-Myers Squibb
  • Panelist Niels Emmerich - Senior Director, Head Search and Evaluation Oncology, AbbVie
  • Panelist Bernd Mühlenweg - CBO, Nanobiotix
  • Panelist Stefanos Theoharis - Senior VP, Corporate Development and Partnering, Cell Medica
  • Panelist Pierre Vandepapelière - CEO, Imcyse

13:30 14:30 (60 mins)

Main agenda

How EU companies can succeed outside of the EU

Level 2, Room 3

Uncertainty is never good for business and this year has seen its fair share of upheaval. This uncertainty has raised questions about funding, research, and healthcare policy, questions which will have knock-on effects on business development and commercialization strategies for EU companies. Within this atmosphere of change, European companies will face unique challenges in the coming years, on a variety of fronts. How can EU companies operate, partner and ultimately succeed outside of the EU? Join us as this panel discusses the importance of alliances and collaboration in managing these transitional times.

  • Moderator Andrea L.C. Reid - Partner,, Dechert LLP
  • Panelist Alex Ibrahim - Head of International Capital Markets, New York Stock Exchange
  • Panelist Olivier Litzka - Partner, Edmond de Rothschild Investment Partners
  • Panelist Sean Marett - COO, BioNTech
  • Panelist Wendell Taylor - VP, Business Development, Vertex Pharmaceuticals

14:45 15:45 (60 mins)

Main agenda

Navigating the post-deal landscape

Level 2, Room 3

In a complex market place characterized by increased government regulation, persistent generic competition, reduced periods of patent exclusivity, and the heavy weight of third-party payers, pharmaceutical and biotech industry executives must explore various options for maximizing product potential throughout the life cycle.  It’s now more important than ever – and earlier in the lifecycle than ever – to devise and implement a strategy to prime a new asset for success at launch and sustain future growth and performance.  This includes taking steps before, throughout and after acquiring an asset to engage the market, and build relationships to understand the needs of patients and other stakeholders in order to inform the strategy.  Join industry experts as they discuss the role of strategy, communications, marketing, patient advocacy and more share case studies and discuss the critical steps necessary to give a new asset a fighting chance before the ink has dried on the contract.

  • Moderator Joanne Wunder - European Managing Director, PR, inVentiv Health
  • Panelist Frank Grams - Head of R&D Alliances, Sanofi
  • Panelist Tom Graney - CFO, Ironwood Pharmaceuticals
  • Panelist Ian Henshaw - Global Head of Business Operations and Alliance Management, Biogen
  • Panelist Neil Hughes - Product Strategy Lead, Endocrinology, Shire
  • Panelist Nerida Scott - Senior Director, Transactions, Johnson & Johnson Innovation

16:00 17:00 (60 mins)

Main agenda

Funding the funders: Insight into the funders of VC healthcare investment

Level 2, Room 3

Venture capitalists are the public face of innovative healthcare funding but they also go through fundraising rounds. Who are the people and organizations who ultimately bankroll biotech businesses? What are their markers of success and what do they demand not only of VCs but also of the portfolio companies that VCs invested in? This panel will host a number of limited partners who have long experience in working with healthcare-focused VCs. Participate in this panel to gain insight into the full picture of global biotech investment.

  • Moderator Hubert Birner - Managing Partner, TVM Life Science Management Inc.
  • Panelist Cedric Bisson - Partner, Teralys Capital
  • Panelist Vanessa Grant - Partner, Norton Rose Fulbright Canada
  • Panelist Johnston Erwin - VP, Strategy and Operations, Corporate Business Development, Eli Lilly
  • Panelist Andrew Smith - VP, Alternative Assets, Advantus Capital Partners

17:15 18:15 (60 mins)

Main agenda

Dealmaking: Structures and stories

Level 2, Room 3

The process of dealmaking is never straightforward, but paying attention to the subtleties of negotiation can play an important part in success. The soft factors that influence the final deal can involve internal financial and legal considerations, corporate culture differences, and negotiation processes and structures. Mastering the intricacies of these underlying factors of negotiation success can mean not only getting the deal done but also determine the success or failure of its implementation. This session will examine the soft factors that impact negotiations and strategies for managing them.

  • Moderator Peter Homberg - Partner, Dentons
  • Panelist Graham Brazier - VP, Business Development, Bristol-Myers Squibb
  • Panelist Peter Buckel, Life Science Management Consulting
  • Panelist Peter Dudek - Principal, Wellington Partners
  • Panelist Jeanette Evans - Executive Director, Business Development and Licensing, MSD
  • Panelist Don O'Sullivan - Global Head, Immunology and Infectious Diseases, Genentech Partnering

13:30 14:30 (60 mins)

Main agenda

Your microbiome and lifelong health

Level 2, Room 2

The Human Healthcycle track begins with an insightful discussion about the lifelong health impact of our individual microbiomes. One of the hottest areas of current research, bolstered by recent investment by the US Government and numerous large-scale research initiatives in North America, Europe and Asia, our growing understanding of the human microbiome suggests breakthroughs in identification, diagnosis and potential treatment in multiple disease areas. From childhood allergies to Parkinson's disease, obesity to antibiotic-resistant bacterial infections, the early stages of microbiome research indicate that our individual and societal health is at once more complex and interconnected with the environment around us than ever. As well as exploring the latest research, this panel will also look at how potential applications of microbiome findings can support a shift to more preventative and holistic approaches to human health and how a greater awareness of the 100 trillion microbia in and on our bodies can contribute to lifelong health management.

  • Moderator Eric de La Fortelle - Venture Partner, Seventure
  • Panelist Isabelle de Crémoux - CEO, Seventure
  • Panelist Daniel Couto - Senior VP, Process Development and Manufacturing, Vedanta BioSciences
  • Panelist Gregory Lambert - CEO, TargEDys
  • Panelist Filip Scheperjans - CEO, NeuroInnovation Oy and Neurologist, Helsinki University Central Hospital
  • Panelist Michal SIlverberg - Senior Director, Takeda Ventures

14:45 15:45 (60 mins)

Main agenda

An autobahn for rare drug development

Level 2, Room 2

There are more than 7,000 rare diseases affecting estimated 350 million people worldwide with fewer than approximately 400 approved treatments, many of which need to be specifically geared towards children.  There are multiple challenges associated with developing meaningful rare genetic disease therapies. In particular, small patient populations make it difficult to design and develop clinical trials for drugs for rare diseases, and on the science side, navigating the regulatory path can be a daunting process. In response to these unique demands, alternative development pathways need to be explored. How do scientists, advocacy groups, biotechs, and investors collaborate on the path to develop impactful rare genetic disease therapies? How do the players accelerate the process of identifying, evaluating, developing potential rare disease therapies and eventually bringing them to people living with rare genetic diseases? This panel will address advances in rare drug innovation, highlight new, efficient paths to advancing therapeutics for rare diseases and examine the role of collaboration in making treatments reality.

  • Moderator James McArthur - CEO, Imara, Inc.
  • Panelist Chris Adams - Co-Founder and CEO , Cydan Development
  • Panelist Kim Andersen - Senior VP and Head of Research, H. Lundbeck A/S
  • Panelist Daria Julkowska - Scientific Coordinator, E-Rare
  • Panelist Debra Miller - President and CEO, CureDuchenne/CureDuchenne Ventures
  • Panelist Mike Pistone - Director of Marketing, Innovation and Commercialization, Cincinnati Children's Hospital

16:00 17:00 (60 mins)

Main agenda

Lifestyle diseases and longevity

Level 2, Room 2

Long term health is now more often a matter of chronic disease management. From the day-to-day grappling with diet and exercise to the more serious repercussions of diabetes, obesity and heart disease, the growth of lifestyle diseases has not only put unprecedented pressure on healthcare systems but also spurred the development of new approaches to drug development, delivery and treatment. Multifaceted approaches to treatment have also prompted new levels of collaboration between companies, healthcare providers, policy makers and patients. This panel will examine not only new treatments but the systemic shifts that have developed in response to the proliferation of these diseases.

  • Moderator Hartmut Ruetten - Head, Translational Medicines, Sanofi
  • Panelist Dorte Gram - CEO, Pila Pharma
  • Panelist Tomas Landh - Innovation Sourcing VP, Senior Principal Scientist, Novo Nordisk
  • Panelist Alexis Normand - Healthcare Development Director, Withings - Nokia Digital Health
  • Panelist Prof. Freimut Schliess - Director Science & Innovation, Profil GmbH, Neuss

17:15 18:15 (60 mins)

Main agenda

The new frontier: Aging and health

Level 2, Room 2

An increasing older population is a well-known characteristic of many countries in Europe but also around the world. The strain put on healthcare and social support systems by this demographic trend has lent an increasing urgency to research into both age-related diseases, such as dementia, but also tools and systems to support healthy aging processes. This panel will explore healthy aging as a process that involves proactive prevention and treatments developed with new understanding of how and why health declines over time.

  • Moderator John Carroll - Co-Founder and Editor, Endpoints
  • Panelist Adam Antebi - Director, Max Planck Institute for Biology of Ageing
  • Panelist Sylvie Bove - CEO, EIT Health
  • Panelist Peter-Andreas Loeschmann - Senior Medical Director, Germany and Medical Lead Internal Medicine, Pfizer Innovative Health
  • Panelist Gregor MacDonald - Senior Director, Neuroscience, Janssen Business Development, Johnson & Johnson

16:00 16:30 (30 mins)

Main agenda

Break and Breathe

Location: Level 2, Conference Room D

Enhance your conference experience by using simple breathing techniques, movement and light stretches in order to charge your body and mind for better decision making and more energy throughout the day. 

Open to all. No prerequisites required. Standing and seated positions only.


18:00 18:45 (45 mins)

Main agenda

Champagne reception at EBD Group booth

Level 0, Hall 7, Booth #80

19:00 22:30 (210 mins)

Main agenda

Evening Networking Reception with Buffet-style Dinner

Location:

Gürzenich Köln  

Martinstraße 29 - 37

50667  Cologne

 

About the location:

COLOGNE’S FRONT PARLOR

The Gürzenich, a popular and traditional Cologne venue, has a history of over 550 years. Built by the City Council as a civic ballroom and market hall between 1441 and 1447, the Gürzenich has served as a cultural center for carnival and musical events for centuries, providing the foundation tor Cologne’s international reputation as a music city. Largely preserving and conserving the substance of the historic monument, the Gürzenich was restored in 1996–97 and today is an exciting venue for social and cultural events.

 

Buses:

18:45–19:15 Shuttle buses depart from the conference center to the evening event.

21:30–22:30 Shuttle buses depart from the evening event to all conference hotels.